SAN DIEGO — It was Novo Nordisk’s Ozempic and Wegovy that set off a brand new period in weight problems drugs, delivering unprecedented ranges of weight reduction and dealing its manner into common tradition, inescapable adverts, and a whole bunch of hundreds of medication cupboards.
However Eli Lilly has been following shut behind with new therapies, and after dropping end result after end result from profitable trials on the American Diabetes Affiliation convention right here this previous weekend, the Indianapolis-based drugmaker appears to be gaining an edge over its Danish competitor within the race to produce weight problems medicine.
From an efficient weight problems tablet, to using its diabetes drug Mounjaro in weight reduction, and eventually to a extremely anticipated injectable that minimize probably the most weight seen with any weight problems drug, Lilly showcased a slew of promising new therapies to the over 11,000 attendees.
Unlock this text by subscribing to STAT+ and revel in your first 30 days free!
GET STARTED
